Search Icon
DRRX Archived Articles

DURECT Corporation (NASDAQ:DRRX) – Pioneering Epigenetic Therapies to Transform Serious Conditions

Published on November 30, 2024

DRRX: Larsucosterol Demonstrates Compelling Efficacy in Phase 2b Trial, Positioning It for Potential Blockbuster Opportunity in Alcohol-Associated Hepatitis

Published on September 24, 2024